Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.
Caballero-Velázquez T, Pérez-López O, Yeguas Bermejo A, Rodríguez Arbolí E, Colado Varela E, Sempere Talens A, Vidriales MB, Solé-Rodríguez M, Quirós Caso C, Pérez López E, Reinoso Segura M, Prats-Martín C, Montesinos P, Pérez-Simón JA. Caballero-Velázquez T, et al. Among authors: perez lopez o, perez lopez e, perez simon ja. Cancers (Basel). 2023 Mar 5;15(5):1609. doi: 10.3390/cancers15051609. Cancers (Basel). 2023. PMID: 36900400 Free PMC article.
[Non-secretory myeloma].
Miras Parra FJ, Ferrer González MA, Pérez López E, Gómez Jiménez FJ, Tornero Ramos C. Miras Parra FJ, et al. Among authors: perez lopez e. An Med Interna. 1994 Oct;11(10):518. An Med Interna. 1994. PMID: 7865669 Spanish. No abstract available.
Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
Labrador J, López-Corral L, López-Godino O, Vázquez L, Cabrero-Calvo M, Pérez-López R, Díez-Campelo M, Sánchez-Guijo F, Pérez-López E, Guerrero C, Alberca I, Del Cañizo MC, Pérez-Simón JA, González-Porras JR, Caballero D. Labrador J, et al. Among authors: lopez godino o, lopez corral l, perez lopez r, perez lopez e, perez simon ja. Bone Marrow Transplant. 2014 May;49(5):684-90. doi: 10.1038/bmt.2014.17. Epub 2014 Feb 24. Bone Marrow Transplant. 2014. PMID: 24566710 Free article.
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia.
Vidriales MB, Pérez-López E, Pegenaute C, Castellanos M, Pérez JJ, Chandía M, Díaz-Mediavilla J, Rayón C, de Las Heras N, Fernández-Abellán P, Cabezudo M, de Coca AG, Alonso JM, Olivier C, Hernández-Rivas JM, Montesinos P, Fernández R, García-Suárez J, García M, Sayas MJ, Paiva B, González M, Orfao A, San Miguel JF; PETHEMA Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group. Vidriales MB, et al. Among authors: perez jj, perez lopez e. Leuk Res. 2016 Jan;40:1-9. doi: 10.1016/j.leukres.2015.10.002. Epub 2015 Oct 22. Leuk Res. 2016. PMID: 26598032
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation.
Caballero-Velázquez T, Calderón-Cabrera C, López-Corral L, Puig N, Marquez-Malaver F, Pérez-López E, García-Calderón C, Rosso-Fernández CM, Caballero Barrigón D, Martín J, Mateos MV, San Miguel J, Pérez-Simón JA; European Myeloma Network. Caballero-Velázquez T, et al. Among authors: lopez corral l, perez lopez e, perez simon ja. Bone Marrow Transplant. 2020 Feb;55(2):419-430. doi: 10.1038/s41409-019-0670-6. Epub 2019 Sep 24. Bone Marrow Transplant. 2020. PMID: 31551517 Clinical Trial.
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.
Martín-Martín L, Gutiérrez-Herrero S, Herrero-García M, Martín García-Sancho A, Yeguas A, Martín-López AÁ, López-Corral L, Pérez-López E, García-Blázquez M, Sánchez-Guijo F, Vidriales MB, Gaipa G; INCAR consortium; EuroFlow consortium; Orfao A. Martín-Martín L, et al. Among authors: perez lopez e. Blood Cancer J. 2024 May 17;14(1):83. doi: 10.1038/s41408-024-01065-z. Blood Cancer J. 2024. PMID: 38760376 Free PMC article. No abstract available.
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
Cabrero M, López-Corral L, Jarque I, de la Cruz-Vicente F, Pérez-López E, Valcárcel D, Sanz J, Espigado I, Ortí G, Martín-Calvo C, de la Serna J, Caballero D; Grupo Español de Trasplante Hematopoyético (GETH) and Grupo Español de Linfomas y Trasplante Autólogo (GELTAMO). Cabrero M, et al. Among authors: perez lopez e. Bone Marrow Transplant. 2024 Mar;59(3):359-365. doi: 10.1038/s41409-023-02171-5. Epub 2024 Jan 2. Bone Marrow Transplant. 2024. PMID: 38167647 Clinical Trial.
Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients.
Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM, Vazquez L, Perez Rivera JA, Martin-Herrero F, Sanchez-Barba M, Guerrero C, del Cañizo MC, Caballero MD, San Miguel JF, Alberca I, Gonzalez-Porras JR. Labrador J, et al. Among authors: lopez corral l, lopez anglada l, perez lopez e, perez rivera ja. Haematologica. 2013 Mar;98(3):437-43. doi: 10.3324/haematol.2012.069559. Epub 2012 Aug 16. Haematologica. 2013. PMID: 22899581 Free PMC article.
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
Cabrero M, Martin A, Briones J, Gayoso J, Jarque I, López J, Grande C, Heras I, Arranz R, Bernal T, Perez-Lopez E, López-Godino O, Conde E, Caballero D. Cabrero M, et al. Among authors: lopez godino o, lopez j, perez lopez e. Biol Blood Marrow Transplant. 2017 Jan;23(1):53-59. doi: 10.1016/j.bbmt.2016.10.003. Epub 2016 Oct 19. Biol Blood Marrow Transplant. 2017. PMID: 27771496 Free article. Clinical Trial.
62 results